BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

740 related articles for article (PubMed ID: 28756230)

  • 1. Haloperidol, a sigma receptor 1 antagonist, promotes ferroptosis in hepatocellular carcinoma cells.
    Bai T; Wang S; Zhao Y; Zhu R; Wang W; Sun Y
    Biochem Biophys Res Commun; 2017 Sep; 491(4):919-925. PubMed ID: 28756230
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sigma-1 receptor protects against ferroptosis in hepatocellular carcinoma cells.
    Bai T; Lei P; Zhou H; Liang R; Zhu R; Wang W; Zhou L; Sun Y
    J Cell Mol Med; 2019 Nov; 23(11):7349-7359. PubMed ID: 31507082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
    Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
    Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The retinoblastoma (Rb) protein regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma cells.
    Louandre C; Marcq I; Bouhlal H; Lachaier E; Godin C; Saidak Z; François C; Chatelain D; Debuysscher V; Barbare JC; Chauffert B; Galmiche A
    Cancer Lett; 2015 Jan; 356(2 Pt B):971-7. PubMed ID: 25444922
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of a novel oxidative stress induced cell death by Sorafenib and oleanolic acid in human hepatocellular carcinoma cells.
    Lange M; Abhari BA; Hinrichs TM; Fulda S; Liese J
    Biochem Pharmacol; 2016 Oct; 118():9-17. PubMed ID: 27544320
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib induces ferroptosis in human cancer cell lines originating from different solid tumors.
    Lachaier E; Louandre C; Godin C; Saidak Z; Baert M; Diouf M; Chauffert B; Galmiche A
    Anticancer Res; 2014 Nov; 34(11):6417-22. PubMed ID: 25368241
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Validation of VX2 as a Hepatocellular Carcinoma Model: Comparison of the Molecular Reaction of VX2 and HepG2 Tumor Cells to Sorafenib In Vitro.
    Nass N; Streit S; Wybranski C; Jürgens J; Brauner J; Schulz N; Powerski M; Ricke J; Kalinski T; Dudeck O; Seidensticker M
    Anticancer Res; 2017 Jan; 37(1):87-93. PubMed ID: 28011478
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ferroptosis and Cell Death Analysis by Flow Cytometry.
    Chen D; Eyupoglu IY; Savaskan N
    Methods Mol Biol; 2017; 1601():71-77. PubMed ID: 28470518
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Activation of the p62-Keap1-NRF2 pathway protects against ferroptosis in hepatocellular carcinoma cells.
    Sun X; Ou Z; Chen R; Niu X; Chen D; Kang R; Tang D
    Hepatology; 2016 Jan; 63(1):173-84. PubMed ID: 26403645
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A combination of sorafenib and SC-43 is a synergistic SHP-1 agonist duo to advance hepatocellular carcinoma therapy.
    Chao TI; Tai WT; Hung MH; Tsai MH; Chen MH; Chang MJ; Shiau CW; Chen KF
    Cancer Lett; 2016 Feb; 371(2):205-13. PubMed ID: 26679051
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ceruloplasmin suppresses ferroptosis by regulating iron homeostasis in hepatocellular carcinoma cells.
    Shang Y; Luo M; Yao F; Wang S; Yuan Z; Yang Y
    Cell Signal; 2020 Aug; 72():109633. PubMed ID: 32283255
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypoxia-mediated sorafenib resistance can be overcome by EF24 through Von Hippel-Lindau tumor suppressor-dependent HIF-1α inhibition in hepatocellular carcinoma.
    Liang Y; Zheng T; Song R; Wang J; Yin D; Wang L; Liu H; Tian L; Fang X; Meng X; Jiang H; Liu J; Liu L
    Hepatology; 2013 May; 57(5):1847-57. PubMed ID: 23299930
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.
    Xu Y; Huang J; Ma L; Shan J; Shen J; Yang Z; Liu L; Luo Y; Yao C; Qian C
    Cancer Lett; 2016 Feb; 371(2):171-81. PubMed ID: 26655273
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metallothionein-1 as a biomarker of altered redox metabolism in hepatocellular carcinoma cells exposed to sorafenib.
    Houessinon A; François C; Sauzay C; Louandre C; Mongelard G; Godin C; Bodeau S; Takahashi S; Saidak Z; Gutierrez L; Régimbeau JM; Barget N; Barbare JC; Ganne N; Chauffert B; Coriat R; Galmiche A
    Mol Cancer; 2016 May; 15(1):38. PubMed ID: 27184800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
    Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
    Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy.
    Prieto-Domínguez N; Ordóñez R; Fernández A; Méndez-Blanco C; Baulies A; Garcia-Ruiz C; Fernández-Checa JC; Mauriz JL; González-Gallego J
    J Pineal Res; 2016 Oct; 61(3):396-407. PubMed ID: 27484637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synergistic anticancer activity of 20(S)-Ginsenoside Rg3 and Sorafenib in hepatocellular carcinoma by modulating PTEN/Akt signaling pathway.
    Lu M; Fei Z; Zhang G
    Biomed Pharmacother; 2018 Jan; 97():1282-1288. PubMed ID: 29156516
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of AMP-activated protein kinase by retinoic acid sensitizes hepatocellular carcinoma cells to apoptosis induced by sorafenib.
    Ishijima N; Kanki K; Shimizu H; Shiota G
    Cancer Sci; 2015 May; 106(5):567-75. PubMed ID: 25683251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. pERK/pAkt phenotyping in circulating tumor cells as a biomarker for sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Li J; Shi L; Zhang X; Sun B; Yang Y; Ge N; Liu H; Yang X; Chen L; Qian H; Wu M; Yin Z
    Oncotarget; 2016 Jan; 7(3):2646-59. PubMed ID: 26544731
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
    Chen B; Wei W; Ma L; Yang B; Gill RM; Chua MS; Butte AJ; So S
    Gastroenterology; 2017 Jun; 152(8):2022-2036. PubMed ID: 28284560
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 37.